https://scholars.lib.ntu.edu.tw/handle/123456789/627205
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Verset, Gontran | en_US |
dc.contributor.author | Borbath, Ivan | en_US |
dc.contributor.author | Karwal, Mark | en_US |
dc.contributor.author | Verslype, Chris | en_US |
dc.contributor.author | Van Vlierberghe, Hans | en_US |
dc.contributor.author | Kardosh, Adel | en_US |
dc.contributor.author | Zagonel, Vittorina | en_US |
dc.contributor.author | Stal, Per | en_US |
dc.contributor.author | Sarker, Debashis | en_US |
dc.contributor.author | Palmer, Daniel H | en_US |
dc.contributor.author | Vogel, Arndt | en_US |
dc.contributor.author | Edeline, Julien | en_US |
dc.contributor.author | Cattan, Stephane | en_US |
dc.contributor.author | Kudo, Masatoshi | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Ogasawara, Sadahisa | en_US |
dc.contributor.author | Daniele, Bruno | en_US |
dc.contributor.author | Chan, Stephen L | en_US |
dc.contributor.author | Knox, Jennifer J | en_US |
dc.contributor.author | Qin, Shukui | en_US |
dc.contributor.author | Siegel, Abby B | en_US |
dc.contributor.author | Chisamore, Michael | en_US |
dc.contributor.author | Hatogai, Ken | en_US |
dc.contributor.author | Wang, Anran | en_US |
dc.contributor.author | Finn, Richard S | en_US |
dc.contributor.author | Zhu, Andrew X | en_US |
dc.date.accessioned | 2023-01-12T05:34:38Z | - |
dc.date.available | 2023-01-12T05:34:38Z | - |
dc.date.issued | 2022-06-13 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/627205 | - |
dc.description.abstract | KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior systemic therapy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | AMER ASSOC CANCER RESEARCH | en_US |
dc.relation.ispartof | Clinical cancer research : an official journal of the American Association for Cancer Research | en_US |
dc.subject | SORAFENIB; BEVACIZUMAB; CRITERIA; PLUS | en_US |
dc.title | Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-3807 | - |
dc.identifier.pmid | 35421228 | - |
dc.identifier.scopus | 2-s2.0-85131902610 | - |
dc.identifier.isi | WOS:000813198400001 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85131902610 | - |
dc.relation.pages | 2547 | en_US |
dc.relation.journalvolume | 28 | en_US |
dc.relation.journalissue | 12 | en_US |
dc.relation.pageend | 2554 | en_US |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。